3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
70
Neoplasms
47
Carcinoma, Non-Small-Cell Lung
26
Colorectal Neoplasms
20
Neoplasm Metastasis
15
Multiple Myeloma
14
Thyroid Neoplasms
12
Glioma
12
Pancreatic Neoplasms
11
Hematologic Neoplasms
10
Thyroid Carcinoma, Anaplastic
9
Brain Neoplasms
8
Lung Neoplasms
7
Triple Negative Breast Neoplasms
5
Rectal Neoplasms
5
Neurofibromatosis 1
5
Lymphoma
5
Leukemia, Myeloid, Acute
5
Colonic Neoplasms
5
Breast Neoplasms
5
Astrocytoma
5
Thyroid Cancer, Papillary
4
Prostatic Neoplasms
4
Neurofibroma, Plexiform
4
Glioblastoma
4
Cholangiocarcinoma
4
Biliary Tract Neoplasms
4
Uveal Melanoma
3
Skin Neoplasms
3
Recurrence
3
Interventions
Gemcitabine
6
Cisplatin
6
Capecitabine
6
Liver Transplantation
4
Fluorouracil
4
Specimen Handling
3
Radiosurgery
3
Oxaliplatin
3
Magnetic Resonance Spectroscopy
3
toripalimab
2
dehydroftorafur
2
Self Expandable Metallic Stents
2
Platinum
2
Leucovorin
2
Biopsy
2
1,2-diaminocyclohexaneplatinum II citrate
2
trisacryl gelatin microspheres
1
tremelimumab
1
trametinib
1
tislelizumab
1
temoporfin
1
sacituzumab govitecan
1
ricolinostat
1
pembrolizumab
1
lenvatinib
1
gemcitabine-oxaliplatin regimen
1
fludarabine
1
durvalumab
1
binimetinib
1
Tegafur
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Klatskin Tumor
×
trametinib
×
Clear all
NCT02042443
2017-09-12
S1310
National Cancer Institute (NCI)
Phase 2
Completed
53 enrolled
13 charts